INTRODUCTION
============

The use of hip arthroscopy for the treatment of patients with hip pathology has increased during the last two decades, with majority performed as outpatient procedures \[[@hnz050-B1], [@hnz050-B2]\]. While minimally invasive in nature, many patients report post-operative pain despite steady narcotic consumption \[[@hnz050-B3]\]. Higher post-operative pain scores are associated with prolonged discharge times \[[@hnz050-B6], [@hnz050-B7]\] and unexpected hospital admission \[[@hnz050-B8]\], resulting in increasing costs incurred by the patient and hospital \[[@hnz050-B9]\]. Post-operative pain in the peri-operative period is of particularly concern as orthopedic procedures have the highest rate of unexpected hospital admissions and incidence of postoperative pain among surgical subspecialties in the setting of ambulatory surgery \[[@hnz050-B5]\]. To date, the ideal peri-operative pain management protocol to effectively decrease pain scores, increase patient satisfaction, allow early mobilization and discharge following arthroscopic hip surgery remains largely unknown \[[@hnz050-B1]\].

In the setting of the current opioid crisis, the use of multimodal pain control regimens has become an increasing focus in orthopedic procedures, including hip arthroscopy, to decrease post-operative narcotic consumption \[[@hnz050-B10]\]. The causes of pain following hip arthroscopy are multifactorial and related to a combination of traction on the operative leg, capsulotomy, labral repair and osteochondroplasty \[[@hnz050-B2], [@hnz050-B6], [@hnz050-B11], [@hnz050-B12]\]. Moreover, the complex innervation of the hip joint and surrounding musculature make effective pain control difficult \[[@hnz050-B13]\]. Current studies have examined the efficacy of peripheral nerve block administration, local injection analgesia, and use of adjunct medications in decreasing post-operative pain and narcotic consumption, while facilitating early discharge following hip arthroscopy \[[@hnz050-B1], [@hnz050-B2], [@hnz050-B8], [@hnz050-B12], [@hnz050-B14]\]. However, no study has evaluated reported post-operative pain outcomes based on pain control regimen. The purpose of this investigation is to provide a comprehensive systematic review of the current literature on peri-operative pain management protocols in patients undergoing arthroscopic hip surgery. The authors hypothesized no significant differences in narcotic consumption, Visual Analog Scale (VAS) score at discharge or incidence of complication depending on pain regimen utilized.

MATERIALS AND METHODS
=====================

A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using a PRISMA checklist \[[@hnz050-B19]\]. All literature pertaining to studies reporting on patients undergoing arthroscopic hip surgery with documented peri-operative pain management regimens published between January 2008 and December 2018 was identified. Two reviewers (J.G.K., D.M.K.) independently conducted a literature search in December 2018 using the following database: Biosis Previews, SPORTdiscus, PEDRO and EMBASE. Each search included the following terms: hip AND arthroscopy AND pain AND management AND nerve block AND analgesia AND outcomes.

Inclusion criteria consisted of English language or articles with English translations, subjects undergoing arthroscopic hip surgery with documented peri-operative pain control protocols in studies reporting Level I to IV evidence. Exclusion criteria were non-English articles, animal studies, prior systematic review or meta-analyses, studies not reporting peri-operative pain control protocols, studies documenting only pediatric (\<18 years of age) patients, studies with Level V evidence and studies with less than five subject participants.

Following the 2 independent authors search of the literature a total of 180 citations were identified. The search process is shown in the flow diagram ([Fig. 1](#hnz050-F1){ref-type="fig"}). Following title and abstract evaluation, a total of 28 articles were selected for further evaluation. Of these studies, 11 studies were excluded due to systematic reviews (*n* = 3 studies), reporting on only pediatric patients (*n* = 1 study), studies not documenting pain control regimens (*n* = 5 studies), studies with \<5 participants (*n* = 2). Following application of the inclusion/exclusion criteria, a total of 17 studies were identified for further analysis. To ensure that all available studies were identified, references cited in the included articles were cross-referenced for inclusion if they were overlooked during the initial search.

![Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flowchart.](hnz050f1){#hnz050-F1}

Patient sex and age at the time of surgery, pain management regimens, time from arrival to discharge from post-anesthesia care unit (PACU), VAS pain score at the time of discharge from PACU, and any complications occurring secondary to pain control interventions or medication were recorded. Narcotic consumption in the PACU was calculated based on morphine equivalents \[[@hnz050-B20]\]. Unexpected hospital admissions due to poorly controlled pain in the immediate post-operative period were also documented. The impact on time to discharge from PACU, VAS score on discharge, PACU narcotic consumption and incidence of complications related to pain regimen was analysed based on: (i) performance of nerve block versus no nerve block, (ii) performance of pre-operative versus post-operative nerve block, (iii) site of nerve block (femoral nerve versus lumbar plexus versus fascia iliac compartment), (iv) performance of isolated nerve block versus nerve block + local analgesic injection versus isolated local injection versus use of only oral or intravenous narcotics. Due to the small size of included studies, Fischer's exact test was used to determine differences between two variables while a one-way analysis of variance was performed when three or more variables were analysed. A *P* values of \<0.05 was used to determine statistical significance. All statistical analyses were performed using SPSS (Version 25.0, IBM, Armonk, NY, USA) software.

QUALITY ASSESSMENT OF INCLUDED EVIDENCE
=======================================

The JADAD quality evaluation scale \[[@hnz050-B21]\] was used to assess the quality of included randomized controlled trials. Studies were assigned a score based on the presence of certain domains (0 = not present, 1 = present and adequate, −1 = present but inadequate). Studies were graded as low quality if they scored 0--1 points, fair quality for 2--3 points or high-quality if they scored 4--5 points. The methodological index for non-randomized studies (MINORS) score \[[@hnz050-B22]\] was used for non-randomized control trial studies which consists of 12 categories (non-comparative studies use only the first 8). Each category is scored out of two points for reported domains (0 = not reported, 1 = reported but inadequate, 2 = reported and adequate). The max score therefore is 16 for non-comparative studies and 24 for comparative studies. An inter-class correlation coefficient was calculated between two authors (J.G.K., D.M.K.) to evaluate agreement between authors using quality appraisal scores. If a score discrepancy was greater than one point between the two authors, the study was evaluated and scored by the senior author (M.J.S.).

RESULTS
=======

The current study includes a combination of blinded randomized control trials and retrospective/prospective cohort studies. In total, 17 articles were included in the present study: 8 randomized controlled trials \[[@hnz050-B2], [@hnz050-B11], [@hnz050-B23], [@hnz050-B24], [@hnz050-B25], [@hnz050-B27], [@hnz050-B29], [@hnz050-B30]\], 7 retrospective \[[@hnz050-B8], [@hnz050-B12], [@hnz050-B14], [@hnz050-B26], [@hnz050-B28]\] and 2 prospective cohort studies \[[@hnz050-B4], [@hnz050-B16]\]. Level 1 evidence made up 47% (*n* = 8 of 17) of the included studies, Level 2 evidence comprised 6% (*n* = 1 of 17) of studies, Level 3 41% (*n* = 7 of 17) and Level 4 6% (*n* = 1 of 17). The mean JADAD score was 4.1 ± 0.6.and the mean MINORS Score was 17.6 ± 3.2 ([Table I](#hnz050-T1){ref-type="table"}) The ICC between the two authors was 0.96, indicating excellent inter-observer agreement, while no study required consultation with the senior author due to score discrepancy of greater than one point.

###### 

Methodology assessment scores of articles

  Study                                   Assessment score \#1   Assessment score \#2
  --------------------------------------- ---------------------- ----------------------
  Philippi *et al*. \[[@hnz050-B26]\]     MINORS score: 13/24    MINORS score: 13/24
  Purcell *et al.*\[[@hnz050-B9]\]        MINORS score: 18/24    MINORS score: 18/24
  Wolff *et al.* \[[@hnz050-B28]\]        MINORS score: 16/24    MINORS score: 16/24
  Baker *et al.* \[[@hnz050-B23]\]        JADAD score: 4/5       JADAD score: 4/5
  Childs *et al.* \[[@hnz050-B10]\]       MINORS score: 20/24    MINORS score: 20/24
  Dold *et al.* \[[@hnz050-B8]\]          MINORS score: 17/24    MINORS score: 17/24
  Kahlenberg *et al.* \[[@hnz050-B25]\]   JADAD score: 4/5       JADAD score: 4/5
  Schroeder *et al.* \[[@hnz050-B12]\]    MINORS score: 18/24    MINORS score: 18/24
  Jaffe *et al.* \[[@hnz050-B14]\]        MINORS score: 18/24    MINORS score: 18/24
  Krych *et al.* \[[@hnz050-B16]\]        MINORS score: 12/16    MINORS score: 12/16
  Shlaifer *et al.* \[[@hnz050-B27]\]     JADAD score: 4/5       JADAD score: 4/5
  Xing *et al.* \[[@hnz050-B2]\]          JADAD score: 5/5       JADAD score: 5/5
  Behrends *et al.* \[[@hnz050-B24]\]     JADAD score: 4/5       JADAD score: 4/5
  Zhang *et al.* \[[@hnz050-B30]\]        JADAD score: 3/5       JADAD score: 3/5
  Potter *et al.* \[[@hnz050-B4]\]        MINORS score: 22/24    MINORS score: 22/24
  Garner *et al.* \[[@hnz050-B11]\]       JADAD score: 4.5/5     JADAD score: 4.5/5
  YaDeua *et al.* \[[@hnz050-B29]\]       JADAD score: 4/5       JADAD score: 4/5

The 17 studies meeting inclusion/exclusion criteria consisted of 1674 patients undergoing arthroscopic hip surgery ([Table II](#hnz050-T2){ref-type="table"}). Mean patient age at the time of surgery was 34.7 ± 3.9 years. Males comprised 37% (*n* = 617) of patients, while patient sex was not reported in one study \[[@hnz050-B12]\]. Mean PACU VAS pain scores at the time of discharge was 4.79 ± 2.04, while VAS scores were not reported in 14 studies \[[@hnz050-B2], [@hnz050-B8], [@hnz050-B9], [@hnz050-B11], [@hnz050-B12], [@hnz050-B14], [@hnz050-B16], [@hnz050-B23]\]. Mean time from arrival to discharge from the PACU was 143.6 ± 57.6 min and not reported in four studies \[[@hnz050-B10], [@hnz050-B11], [@hnz050-B14], [@hnz050-B16]\]. Mean reported post-operative narcotic utilization following surgery while in PACU was 10.9 ± 10.3 mg, while narcotic consumption was not reported in three studies \[[@hnz050-B2], [@hnz050-B16], [@hnz050-B30]\].

###### 

Summary of studies included in review

  Author                                  Journal                                        Level of evidence   Number of patients                                              Age (mean years)                                                                              Sex           Pre-operative block                                       Intra-operative local injection                                                Post- operative block                                         PACU morphine equivalents (mg)                                Time until discharge (Min)   Post- operative pain at discharge (VAS)   Complications                                            Pre- versus post-procedure local injection analgesia   Localization for block                     Procedures performed
  --------------------------------------- ---------------------------------------------- ------------------- --------------------------------------------------------------- --------------------------------------------------------------------------------------------- ------------- --------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------- ------------------------------------------------------------- ---------------------------- ----------------------------------------- -------------------------------------------------------- ------------------------------------------------------ ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Philippi *et al.* \[[@hnz050-B26]\]     *J Hip Preserv Surg* (2018)                    3                   50                                                              25.47                                                                                         14M36F        NR                                                        Extracapsular 20 ml 0.25% bupivacaine-epinephrine (1:200 000)                  *n*=17(FNB)                                                   14.51                                                         151.2                        NR                                        NR                                                       Post-procedure                                         NR                                         NR
  50                                      25.09                                          18M32F              NR                                                              None                                                                                          *n*=28(FNB)   14.08                                                     139.8                                                                          NR                                                            NR                                                                                                                                                                                                                                                                                              
  Purcell *et al.* \[[@hnz050-B9]\]       *Knee Surg Sports Traumatol Arthrosc* (2018)   3                   34                                                              34.7                                                                                          23M11F        FICB40 cc 0.25% plainBupivacaine                          NR                                                                             NR                                                            32.53                                                         110.6                        NR                                        None                                                     NA                                                     US                                         NR
  34                                      32.4                                           15M19F              FICB266 mg liposomal bupivacaine+20 cc 0.5% plain bupivacaine   NR                                                                                            NR            29.46                                                     108.6                                                                          NR                                                            None                                                                                                                                                                                                                                                                                            
  Wolff *et al.* \[[@hnz050-B28]\]        *J Hip Preserv Surg* (2016)                    3                   55                                                              34.51                                                                                         18M37F        None                                                      NR                                                                             NR                                                            7.02                                                          108.6                        NR                                        None                                                     NA                                                     US (FNB, LPB)+nerve stimulator for (LBP)   NR
  30                                      30.57                                          11M19F              FICB40 ml, 0.375% ropivacaine, 4 mg dexamethasone               NR                                                                                            NR            8.8                                                       112.2                                                                          NR                                                            None                                                                                                                                                                                                                                                                                            
  60                                      35.45                                          19M41F              LPB0.375% ropivacaine, 4 mg dexamethasone                       NR                                                                                            NR            7.16                                                      111.5                                                                          NR                                                            Seizure (*n*=1)                                                                                                                                                                                                                                                                                 
  Baker *et al.* \[[@hnz050-B23]\]        *Hip Int* (2011)                               1                   40                                                              37.8                                                                                          26M14F        NR                                                        Intracapsular10 ml of 0.25% bupivacaine                                        NR                                                            0.57                                                          48                           NR                                        NR                                                       Post-procedure                                         NA                                         Labral/chondral tissue debridement; MFX/osteoplasty
  33                                      38.8                                           17M16F              NR                                                              Extracapsular10 ml of 0.25% bupivacaine                                                       NR            2.33                                                      48                                                                             NR                                                            NR                                                                                                                                                                                                                                                                                              
  Childs *et al.* \[[@hnz050-B10]\]       *Arthroscopy* (2017)                           3                   105                                                             33.4                                                                                          38M67F        FNB0.5% bupivacaine with 1:200 000 epinephrine            None                                                                           NR                                                            10.425                                                        NR                           3.55                                      Peripheral Neuritis (*n*=26)Falls (*n*=19)               Post-procedure                                         US                                         Labral debridement/repair/reconstruction; synovectomy; femoral osteochondroplasty
  88                                      31.3                                           27M61F              None                                                            Intracapsular300 mg ropivicaine (0.5%) with epinephrine, 30 mg ketorolac, and 5 mg morphine   NR            12.525                                                    NR                                                                             4.28                                                          Peripheral neuritis (*n*=2)Falls (*n*=5)                                                                                                                                                                                                                                                        
  Dold *et al.* \[[@hnz050-B8]\]          *Am J Sports Med* (2014)                       3                   40                                                              34.2                                                                                          22M18F        None                                                      NR                                                                             NR                                                            4                                                             81.53                        NR                                        Admission for pain (*n*=2)                               NA                                                     US                                         Femoral osteochondroplastyloose body removal; labral debridement
  56                                      33.1                                           37M19F              FNB15--25 ml, 0.33--0.75% ropivacaine                           NR                                                                                            NR            2.04                                                      85.96                                                                          NR                                                            None                                                                                                                                                                                                                                                                                            
  Kahlenberg *et al.* \[[@hnz050-B25]\]   *Arthroscopy* (2017)                           1                   50                                                              34.2                                                                                          24M26F        None                                                      NR                                                                             NR                                                            15.326                                                        152.96                       NR                                        None                                                     NA                                                     NA                                         Labral repair/debridement/reconstruction alone; revision labral repair; Labral repair with acetabular osteoplasty/chondroplasty; labral repair with femoral head chondroplasty
  48                                      35.8                                           19M29F              None                                                            NR                                                                                            NR            15.419                                                    172.96                                                                         NR                                                            None                                                                                                                                                                                                                                                                                            
  Schroeder *et al.* \[[@hnz050-B12]\]    *Hip Int* (2013)                               3                   118                                                             41.1                                                                                          NR            LPB20--30 ml, 0.5% ropivacaine, 3 μg ml^−1^ epinephrine   Intracapsular 4 mg of morphine                                                 NR                                                            5                                                             240                          NR                                        NR                                                       Post-procedure                                         Nerve stimulator                           NR
  118                                     38.7                                           NR                  None                                                            Intracapsular4 mg of morphine                                                                 NR            6.7                                                       217.5                                                                          NR                                                            NR                                                                                                                                                                                                                                                                                              
  Jaffe *et al.* \[[@hnz050-B14]\]        *J Pain Palliat Care Pharmacother* (2017)      3                   141                                                             32.4                                                                                          42M99F        LPB+sciatic block                                         NR                                                                             NR                                                            0                                                             NR                           NR                                        NR                                                       NA                                                     NR                                         NR
  36                                      38.2                                           8M28F               None                                                            NR                                                                                            NR            40.05                                                     NR                                                                             NR                                                            NR                                                                                                                                                                                                                                                                                              
  Krych *et al.* \[[@hnz050-B16]\]        *Knee Surg Sports Traumatol Arthrosc* (2014)   2                   30                                                              34                                                                                            7M23F         FICB40 ml 0.25 % bupivacaine with 1:200 000epinephrine    NR                                                                             NR                                                            NR                                                            NR                           NR                                        None                                                     NA                                                     US                                         Labral repair; femoral osteochondroplasty; pincer resection
  Shlaifer *et al.* \[[@hnz050-B27]\]     *Arthroscopy* (2017)                           1                   21                                                              39.6                                                                                          14M7F         None                                                      Extracapsular20 ml of bupivacaine 0.5%Intracapsular20 ml of bupivacaine 0.5%   NR                                                            3.15                                                          123                          NR                                        None                                                     Pre- and post-procedure                                NA                                         Labral repair/reconstruction; femoral/acetabular osteoplasty
  21                                      36                                             11M10F              None                                                            Intracapsular 20 ml of bupivacaine 0.5%                                                       NR            7.23                                                      213                                                                            NR                                                            None                                                                                                                                                                                                                                                                                            
  Xing *et al.* \[[@hnz050-B2]\]          *Am J Sports Med* (2015)                       1                   27                                                              32                                                                                            21M6F         FNB20 ml, 0.5% ropivacaine, 2.5 μg ml^−1^ epinephrine     NR                                                                             None                                                          NR                                                            246                          NR                                        Falls (*n*=6)                                            NA                                                     US                                         Labral repair; osteochondroplasty
  23                                      31                                             14M9F               None                                                            NR                                                                                            None          NR                                                        252.5                                                                          NR                                                            None                                                                                                                                                                                                                                                                                            
  Behrends *et al.* \[[@hnz050-B24]\]     *Anesthesiology* (2018)                        1                   38                                                              35                                                                                            23M15F        FICB40 ml ropivacaine 0.2%                                Intracapsular10 ml of 0.2% ropivacaine                                         NR                                                            15                                                            123                          NR                                        Falls (*n*=4)                                            Post-procedure                                         US                                         Osteochondroplast; labral repair; loose body removal; screw removal; MFX; debridement
  40                                      32                                             17M23F              None                                                            Intracapsular10 ml of 0.2% ropivacaine                                                        NR            16                                                        128                                                                            NR                                                            Fall (*n*=1)                                                                                                                                                                                                                                                                                    
  Zhang *et al.* \[[@hnz050-B30]\]        *Eur J Orthop Surg Traumatol* (2013)           1                   27                                                              41                                                                                            11M13F        None                                                      NR                                                                             NR                                                            NR                                                            147                          7.23                                      NR                                                       NA                                                     NA                                         NR
  26                                      43.5                                           14M15F              None                                                            NR                                                                                            NR            NR                                                        152                                                                            7.46                                                          NR                                                                                                                                                                                                                                                                                              
  Potter *et al.* \[[@hnz050-B4]\]        *Arthroscopy* (2014)                           4                   53                                                              37.1                                                                                          15M38F        NR                                                        NR                                                                             FICB30 ml 0.25% bupivacaine with 5 mg ml^−1^ of epinephrine   4.4                                                           102                          2.8                                       Admission for pain (*n*=3)                               NA                                                     US                                         Femoral osteoplasty; labral repair; capsular repair; unlisted additional repair
  54                                      34.9                                           26M28F              NR                                                              NR                                                                                            None          4.4                                                       97                                                                             3.4                                                           None                                                                                                                                                                                                                                                                                            
  Garner *et al.* \[[@hnz050-B11]\]       *Arthroscopy* (2017*)*                         1                   20                                                              33.6                                                                                          14M6F         None                                                      Extracapsular40 ml of 0.125% of levobupivacaine                                NR                                                            2.4                                                           NR                           NR                                        None                                                     Post-procedure                                         US                                         Excision of CAM lesion; labral debridement/repair; removal of loose bodies; chondroplasty; MFX
  26                                      31.9                                           11M15F              FICB40 ml, 0.125% levobupivacaine                               None                                                                                          NR            5.5                                                       NR                                                                             NR                                                            None                                                                                                                                                                                                                                                                                            
  YaDeua *et al.* \[[@hnz050-B29]\]       *Anesth Analg* (2012)                          1                   41                                                              37                                                                                            21M20F        None                                                      None                                                                           NR                                                            29                                                            187                          NR                                        Oxygen desaturation (*n*=1) Admission for pain (*n*=1)   NA                                                     Nerve stimulator                           Labral debridement; labral/capsular repair; synovectomy; cam decompression; osteochondroplasty; pincer debridement; subspine decompression; rim decompression; psoas release; loose body removal
  41                                      33                                             20M21F              LPB30 ml, 0.25% bupivacaine, 5 μg ml^−1^ epinephrine            None                                                                                          NR            2                                                         216                                                                            NR                                                            Epidural spread with urinary retention (*n*=1)Falls (*n*=2)                                                                                                                                                                                                                                     

GA, general anesthesia; FICB, fascia iliac compartment block; LPB, lumbar plexus block; FNB, femoral nerve block; LIA, local injection analgesia; CSE, continuous spinal epidural; PA, periacetabular; IA, intra-articular; NR, not reported; PACU, post-anesthesia care unit; VAS, visual analog score; NRS, numeric rating scale; SDCU, surgical day care unit; Min, minutes; mg, milligrams; MFX, microfracture; US, Ultrasound; NR, Not reported; NA, Not applicable.

Nerve blocks were performed in 50% of patients (*n* = 838 of 1674), of which 88% (*n* = 740 of 838) received a pre-operative block while 12% (*n* = 98 of 838) were administered following surgery. Blocks were administered to the: fascia iliaca compartment (29%, *n* = 245 of 838) \[[@hnz050-B4], [@hnz050-B9], [@hnz050-B11], [@hnz050-B16], [@hnz050-B24], [@hnz050-B28]\], femoral nerve (28%, *n* = 233 of 838) \[[@hnz050-B2], [@hnz050-B8], [@hnz050-B10], [@hnz050-B26]\], lumbar plexus (26%, *n* = 219 of 838) \[[@hnz050-B12], [@hnz050-B28], [@hnz050-B29]\] and lumbar plexus + sciatic nerve (17%, *n* = 141 of 838) \[[@hnz050-B14]\]. Blocks were performed either under ultrasound guidance or with the use of a nerve stimulator, with block localization not reported in two studies \[[@hnz050-B14], [@hnz050-B26]\]. Seven studies reported use of local injection analgesia intra-operatively, with injections provided to the intracapsular space (*n* = 5 studies) \[[@hnz050-B10], [@hnz050-B12], [@hnz050-B23], [@hnz050-B24], [@hnz050-B27]\], extracapsular space (*n* = 3 studies) \[[@hnz050-B11], [@hnz050-B23], [@hnz050-B26]\], or both intra-and extracapsular spaces (*n* = 1 study) \[[@hnz050-B27]\]. Statistical analysis found no significant difference in consumption of narcotic pain medication in PACU, time until PACU discharge, VAS scores on discharge, or the incidence of complications based on pain control regimen ([Table III](#hnz050-T3){ref-type="table"}). Time from PACU arrival to discharge was not significantly different in patients provided with femoral nerve blocks (mean, 166 min) compared with those receiving fascia iliac compartment (mean, 111 min) or lumbar plexus blocks (mean 189 min) (*P* = 0.21).

###### 

Fischer's exact test and analysis of variables based on pain control modality

                                                                                   *P*-value                
  -------------------------------------------------------------------------------- ----------- ------ ----- ------
  Nerve block only versus no nerve block                                           0.89        0.75   0.1   0.3
  Pre-operative nerve block versus post-operative nerve block                      --          --     --    --
  Nerve block only versus nerve block + LIA                                        0.58        0.85   --    --
  LIA pre and post versus LIA post-procedure                                       0.62        0.28   --    0.24
  LIA only versus LIA + nerve block                                                0.53        0.6    --    --
  FNB versus LPB versus FICB block                                                 0.21        0.16   --    0.17
  Nerve block only versus nerve block + LIA versus LIA only                        0.64        0.53   --    0.86
  Nerve block only versus nerve block +LIA versus LIA only versus narcotics only   0.74        0.35   --    0.75

LIA, local injection analgesia; FNB, femoral nerve block; LPB, lumbar plexus nerve block; FICB, fascia iliac compartment block; Meq, narcotic use based on calculated morphine equivalents; VAS, visual analog score; PACU, post-anesthesia care unit.

Statistical significance.

A total of 68 complications related to post-operative pain management interventions were reported in 5 studies. Reported complications included: falls (54%, *n* = 37 patients) \[[@hnz050-B2], [@hnz050-B10], [@hnz050-B24], [@hnz050-B29]\], peripheral neuritis (41%, *n* = 28 patients) \[[@hnz050-B10]\], seizure (1.5%, *n* = 1 patient) \[[@hnz050-B28]\], oxygen desaturation and nausea (1.5%, *n* = 1 patient) \[[@hnz050-B29]\], and epidural spread resulting in urinary retention (1.5%, *n* = 1 patient) \[[@hnz050-B29]\]. Eighty-four percent (*n* = 31 of 37) of falls occurred in patients receiving a peripheral nerve block, of which 81% (*n* = 25 of 31) of fall patients received a femoral nerve block \[[@hnz050-B2], [@hnz050-B10]\]. No reported falls required further operative intervention. A total of six patients were admitted following surgery due to poorly controlled post-operative pain \[[@hnz050-B4], [@hnz050-B8], [@hnz050-B29]\]. No significant difference was appreciated between patients admitted for poorly controlled pain compared with patients discharged on the day of surgery based on patient age (*P* = 0.60), narcotic consumption in PACU (*P* = 0.86) or time from PACU arrival to discharge (*P* = 0.57).

DISCUSSION
==========

A total of 50% of patients undergoing arthroscopic hip surgery received a peripheral nerve block, with the majority of patients undergoing pre-operative nerve blocks. No significant difference in narcotic consumption in PACU, time until PACU discharge, VAS score on discharge or incidence of complications related to peri-operative pain management was appreciated based on pain control regimen. Patients treated with femoral nerve blocks had higher rate of falls post-operatively compared with fascia iliaca compartment blocks or lumbar plexus blocks. To our knowledge, this investigation represents the largest collection of studies evaluating the impact of peri-operative pain control regimens on outcomes following arthroscopic hip surgery ([Table IV](#hnz050-T4){ref-type="table"}).

###### 

Mean values based on pain control modality utilized

  Pain control modality            Mean time admission to PACU discharge (min)   Mean PACU narcotic utilization (Meq)   Mean VAS at PACU discharge   Mean number of complications
  -------------------------------- --------------------------------------------- -------------------------------------- ---------------------------- ------------------------------
  Nerve block only                 137                                           11.7                                   3.18                         5
  No nerve block                   142                                           11.6                                   5.59                         0.75
  Nerve block (FNB, LBP or FICB)   146                                           10.2                                   3.18                         4.92
  Pre-operative nerve block        150                                           10.7                                   3.55                         5.34
  Post-operative nerve block+      102                                           4.4                                    2.80                         0
  Nerve block + LIA                181.5                                         10                                     --                           4
  LIA post-procedure               137                                           8.75                                   3.92                         9.5
  LIA pre- and post-procedure      168                                           5.19                                   --                           0
  LIA only                         130                                           6.36                                   4.28                         1.60
  FNB                              166                                           6.23                                   3.55                         17
  LBP                              189                                           3.54                                   --                           2
  FICB                             111                                           15.9                                   2.8                          0.57
  Narcotics only                   150                                           16.5                                   6.03                         0.14

LIA, local injection analgesia; FNB, femoral nerve block; LPB, lumbar plexus nerve block; FICB, fascia iliaca compartment block; Meq, narcotic use based on calculated morphine equivalents; VAS, visual analog score; PACU, post-anesthesia care unit; +, denotes single study.

Statistical significance.

Nerve blocks were utilized as part of the pain control regimen in 50% of patients undergoing hip arthroscopy. The use of selective nerve blocks have demonstrated good efficacy in controlling pain following hip fracture fixation, as well as total knee arthroplasty \[[@hnz050-B31], [@hnz050-B32]\]. One retrospective review found that patients who underwent pre-operative femoral nerve blocks prior to hip arthroscopy reported significantly lower pain scores 1 h following PACU arrival, required lower PACU morphine equivalent doses, and experienced no unexpected admissions due to poorly controlled pain compared with control patients not receiving femoral nerve blocks \[[@hnz050-B8]\]. Another retrospective review found that patients who received a pre-operative lumbar plexus block in addition to standard intra-articular injection of morphine reported significantly reduced immediate and peak postoperative recovery pain scores, as well as decreased narcotic consumption post-operatively when compared with control patients \[[@hnz050-B12]\]. As such, the utilization of selective nerve blocks has become increasingly common for the control of post-operative pain following hip arthroscopy. The current investigation found that patients treated with FICB (mean 111 min) experienced shorter times to discharge when compared with FNB (mean 166 min) and LPB (mean 189 min). While not statistically significant, the shorter PACU stay times for FICB blocks could result in decrease hospital costs. A recent analysis on operating room and PACU cost found that PACU operations were ∼\$12.14 per minute for services offered \[[@hnz050-B33]\]. Thus, hospital costs could be theoretically decreased with shorter PACU stays based on the type of nerve block provided. However, in order to delineate these cost savings and benefits, future studies examining different outcome variables based on types of nerve blocks performed for hip arthroscopy are warranted.

Local analgesia alone or when administered with nerve blocks was not found to significantly change post-operative pain outcomes. Local injections are generally provided to effectively control localized pain and supplement the anatomical areas missed by peripheral nerve blocks, specifically the hip capsule. Difficulty in controlling pain from the hip capsule occurs as a result of its complex innervation from the network of surrounding nerves: the anterior and medial capsule being innervated by the femoral and obturator nerves while the posterior and lateral capsule are innervated by the sciatic, superior gluteal and nerve to quadratus femoris \[[@hnz050-B13]\]. One randomized control trial reported that patients treated with local analgesia to the hip capsule versus FICB nerve blocks had significantly lower PACU pain scores, hypothesizing that the innervation provided by the sciatic, superior gluteal and nerve to quadratus femoris to the hip capsule were not treated using an FICB block \[[@hnz050-B11]\]. The same study also proposed that local analgesia injections diffuse outside the portal tracts, thereby more completely anesthetizing the hip capsule/joint \[[@hnz050-B11]\]. Moreover, the concentration of diffused local anesthetic effectively block the fibers responsible for pain, lacking the potency to block motor fibers, decreasing fall risks \[[@hnz050-B11]\]. Other investigations have similarly reported that FICB as well as FNB do not affect nerves from the sacral plexus innervating the hip capsule, leading to continued hip pain with the potential for admission for pain control \[[@hnz050-B4], [@hnz050-B9], [@hnz050-B28]\]. When compared with extra-capsular injection, one study reported that intra-capsular injections have been shown to result in significantly lower morphine requirements in the immediate post-operative period \[[@hnz050-B23]\]. The authors further hypothesized that a combination of intra-articular and portal local injection analgesia to be optimal for post-operative pain control \[[@hnz050-B23]\].

While no differences in the incidence of complications were reported based on pain regimen, peripheral nerve blocks and local anesthesia injections each carry the potential for complications. Falls remains a significant area of concern following peripheral nerve blocks in hip surgery due to muscle weakness and neuraxial spread \[[@hnz050-B10], [@hnz050-B24], [@hnz050-B29]\]. One retrospective review reported that patients receiving femoral nerve blocks had over 3× the fall risk and 14× the risk for post-operative neuropathy when compared with local injection anesthesia \[[@hnz050-B10]\]. Meanwhile, intra-articular injections possess the potential for chondrotoxic effects, with one study reporting that a single intra articular injection of bupivacaine into the knees of rat subjects resulted in a 50% decrease in chondrocyte density compared with saline-injected rat knees after 6 months \[[@hnz050-B34]\]. As such, post-operative precautions must be taken into consideration in patients undergoing utilization of nerve blocks for pain control following hip arthroscopy.

The current study is not without limitations. Due to the heterogeneity and variability of data reporting post-operative pain regimen, the authors utilized surrogate metrics to standardize data to allow for pooled analysis. Moreover, there remains a lack of a standardized reporting measures to evaluate post-operative pain outcomes following arthroscopic hip surgery. Due to limited reported data, the authors were unable to determine differences in outcomes based on the performance of pre-operative versus post-operative nerve blocks or outcomes based on pre-procedural versus post-procedural intra-operative local injection analgesia. As the arthroscopic procedures performed within the hip were not regularly reported nor were outcomes based on procedures performed explicitly reported, the authors were unable to conduct any sub-analysis based on the number and type of arthroscopic procedures performed within the hip. Patients who underwent revision surgeries and those with a history of chronic opiate or narcotic abuse/use were not explicitly excluded in all of the chosen articles, which may alter post-operative outcome scores when compared with primary surgery patients and opiate naive patients. In addition, due to heterogeneity of the reported data, the authors were unable to perform any meaningful statistical analysis on pre-operative non-narcotic medication regimens.

In moving forward, the treatment of peri-operative pain following hip arthroscopy will require further investigation using a multiple modal pain control protocol given the complex innervation of the hip capsule and surrounding tissue. Determining the optimal pain protocol will involve providing appropriate sensory anesthesia for pain control while preserving motor function to prevent the incidence of falls and other associated injuries in the acute postoperative period. The senior author's institution has implemented a novel opiate sparing pain protocol for peri-operative pain control following arthroscopic hip surgery that includes non-narcotic preoperative pain medications (acetaminophen, celecoxib, neurontin); preoperative ultrasound-guided pure sensory transversalis fascia plane block performed by a fellowship-trained anesthesiologist; the use of both intra capsular and portal site local injection analgesia; muscle relaxer to combat spasms; and the use of anti-inflammatory postoperative pain medication with minimal postoperative narcotics utilization. Further prospective studies utilizing a combination of peripheral nerve block, peri-operative and postoperative pain control with minimal use of narcotics are necessary to help better understand the best methods of treating the complex series of pain generators activated following hip arthroscopy.

In conclusion, no statistically significant difference in PACU narcotic utilization, time to discharge, VAS pain scores at discharge or incidence of complications was appreciated when comparing different peri-operative pain regimens following hip arthroscopy in the present study. Further research and standardization of pain control regimens is required to determine the best protocol for the treatment of postoperative pain during the peri-operative period to optimize patient satisfaction, allow early mobilization and decease number of pain-related complications.
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